TEL-AVIV, Israel, Jan.
04, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL)
(“RedHill” or the “Company”), a specialty biopharmaceutical company primarily
focused on the development and commercialization of late clinical-stage, proprietary,
orally-administered, small molecule drugs for gastrointestinal and inflammatory
diseases and cancer, today announced that the underwriters of its previously
announced underwritten public offering of 2,250,000 American Depository Shares
(“ADSs”), each representing 10 of its ordinary shares, and warrants to purchase
1,125,000 ADSs, have partially exercised their option and purchased 133,104
ADSs.
Source : RedHill
Biopharma Ltd.
No comments:
Post a Comment